How does CooperCompanies make money?

COOPER COMPANIES, INC. – Business Breakdown

The Essentials

The Cooper Companies, Inc. is organized around two operating platforms: CooperVision and CooperSurgical. CooperVision is centered on contact lenses for vision correction, spanning spherical, toric, multifocal, and myopia management products. CooperSurgical serves the fertility and women’s health ecosystem through fertility products and services, women’s health medical devices, contraception, and cryostorage.

From the filings provided, the company appears to be a diversified healthcare and vision-care franchise with meaningful scale, generating $4.09 billion of revenue in FY2025, up 5% year over year on both reported and constant-currency terms, with 4% organic growth. The business is global in orientation, but the source does not provide a granular geographic or segment revenue split. Financially, the profile indicates a business with strong profitability characteristics, including a 66% GAAP gross margin and 17% GAAP operating margin, both of which improve materially on a non-GAAP basis.

Business Model & Revenue Drivers

The company’s economic engine is built on two distinct but complementary revenue streams:

• CooperVision

  • Generates revenue from contact lenses used for vision correction.
  • The product set includes spherical, toric, multifocal, and myopia management lenses.
  • The filings indicate focus on global contact lens wearers, with growth supported by product innovation, distribution, and selling/promotional activity.
  • The business is exposed to competitive pricing, product quality differentiation, and supply chain inputs, particularly raw materials for silicone hydrogel lenses.

• CooperSurgical

  • Generates revenue from fertility products and services, women’s health medical devices, contraception, and cryostorage.
  • The segment serves fertility clinics and office/surgical products customers.
  • Growth is tied to portfolio breadth, integrated solutions, and the company’s ability to respond to consolidation among OB/GYN and fertility customers.
  • The filings suggest ongoing strategic investment in fertility and women’s health capabilities, though no detailed revenue mix is provided.

At the consolidated level, the company produced $796.1 million of cash from operations in FY2025, indicating solid cash conversion. Inventory stood at $846.0 million and net PP&E at $2.082 billion, underscoring a meaningful manufacturing and operating footprint.

Strategic Edge & Market Positioning

Economic Moat:
Based strictly on the provided filings, there is no clear evidence of a durable structural moat. The source does not point to network effects, entrenched switching costs, cost leadership, or patent protection strong enough to constitute a lasting barrier to entry. The markets are described as highly competitive, with competition driven by technological advances, product quality, price, and customer service. That framing suggests a sector where differentiation must be continuously earned rather than structurally protected.

Execution Advantage:
The company does appear to have an execution-based advantage in several areas:

• It is able to sustain growth while expanding margins, with non-GAAP gross margin at 68% and non-GAAP operating margin at 26%, both up 100 bps year over year.
• CooperVision benefits from active investment in distribution, packaging, and promotional activity, particularly around single-use and myopia management modalities.
• CooperSurgical appears positioned to capitalize on customer consolidation in fertility and OB/GYN through a broad portfolio and integrated offering set.
• The company’s scale and product breadth likely support account penetration and cross-selling, but the filings do not establish this as a structural moat.

The competitive backdrop remains exposed to commoditization risk, regulatory friction, product recalls, litigation, and supply chain vulnerabilities, all of which can pressure pricing power and operating leverage.

Outlook & Innovation Pipeline

The filings do not provide a formal three-year strategic plan, but they do indicate the company’s near-term priorities and innovation focus:

• FY2026 priorities

  • Accelerate top-line growth
  • Improve profitability
  • Increase cash generation
  • Return capital to shareholders

• CooperVision roadmap

  • Continued investment in selling and promotional activities
  • Expansion of distribution and packaging support for key lens modalities
  • Ongoing emphasis on myopia management and single-use / FRP-related offerings

• CooperSurgical roadmap

  • Strategic transactions aimed at expanding integrated solutions in fertility and women’s health
  • Continued focus on donor activity, cryopreservation, and outpatient/office-based procedural solutions
  • Portfolio positioning to address consolidation among fertility and OB/GYN customers

Overall, the innovation pipeline appears to be incremental and commercially oriented rather than breakthrough-driven. The filings reference technological and scientific advances as competitive factors, but they do not identify specific patents or transformative R&D programs. The strategic emphasis is therefore on portfolio optimization, channel execution, and margin discipline rather than on a clearly articulated disruptive technology roadmap.